Affordable Access

Treatment of chronic hepatitis C with PEGylated interferon and ribavirin.

Authors
  • Cornberg, Markus
  • Wedemeyer, Heiner
  • Manns, Michael P
Type
Published Article
Journal
Current gastroenterology reports
Publication Date
Feb 01, 2002
Volume
4
Issue
1
Pages
23–30
Identifiers
PMID: 11825538
Source
Medline
License
Unknown

Abstract

Treatment with interferon alfa combined with ribavirin is successful in approximately 40% to 45% of patients with chronic hepatitis C viral infection (HCV). However, response rates are disappointing in patients who are difficult to treat, such as those infected with HCV genotype 1, high viral load, or advanced liver fibrosis. In addition, low tolerability and significant side effects of therapy frequently lead to dose reduction and treatment discontinuation, decreasing response rates further. Thus, investigation of new treatment options and innovations for chronic HCV infection are vital. This review describes recent advances in the treatment of HCV infection with PEGylated interferon (interferon modified with polyethylene glycol [PEG] ) combined with ribavirin.

Report this publication

Statistics

Seen <100 times